MetabolicIn Clinical Trials

Orforglipron

Oral

Overview

Orforglipron is a non-peptide, oral small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist designed to overcome the need for injectable delivery. It activates the GLP-1 receptor to enhance glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying.

Mechanism of Action

The therapeutic rationale centers on improving adherence in type 2 diabetes and obesity management by providing once-daily oral dosing as an alternative to injectable GLP-1 receptor agonists..

Research Summary & Key Findings

Phase 2 trials have demonstrated dose-dependent reductions in HbA1c and body weight in adults with type 2 diabetes, with results presented at major diabetes conferences in 2023. Gastrointestinal adverse events were consistent with the GLP-1 agonist class. Phase 3 development is ongoing to establish efficacy and safety in broader patient populations.

Clinical Status

In Clinical Trials

Orforglipron is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Oral

Related Peptides in Metabolic

Semaglutide (Ozempic/Wegovy)

FDA Approved

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...

View details

Tirzepatide (Mounjaro/Zepbound)

FDA Approved

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...

View details

Retatrutide

In Clinical Trials

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...

View details

AOD-9604

Investigational

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...

View details

Find a Provider

Find a verified provider who offers Orforglipron therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Orforglipron.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.